Comparative Pharmacology
Head-to-head clinical analysis: CABOMETYX versus PONATINIB HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABOMETYX versus PONATINIB HYDROCHLORIDE.
CABOMETYX vs PONATINIB HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, KIT, and FLT3. It inhibits tumor growth, angiogenesis, and metastasis by blocking these pathways.
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
60 mg orally once daily for the first 21 days of a 21-day cycle, with or without food, for renal cell carcinoma; for hepatocellular carcinoma, 60 mg orally once daily.
45 mg orally once daily with or without food.
None Documented
None Documented
Terminal half-life approximately 99 hours (range 80–120 h). Supports once-daily dosing with steady-state achieved within 15 days.
Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Primarily fecal (54%) with minimal renal excretion (27% unchanged drug; <10% as metabolites). Biliary excretion contributes to fecal elimination.
Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor